Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) generates frequent news flow as a clinical-stage biotechnology company developing neflamapimod for dementia with Lewy bodies (DLB) and other age-related brain disorders. The company’s updates often center on clinical data releases, regulatory interactions, and corporate developments tied to its lead program.
Investors following CRVO news can expect detailed announcements on results from the Phase 2b RewinD-LB trial in DLB, including subgroup analyses, biomarker findings, and longer-term extension data. CervoMed has reported that neflamapimod treatment in DLB was associated with effects on the Clinical Dementia Rating – Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), and plasma biomarkers such as glial fibrillary acidic protein (GFAP), Aβ42/40 ratio, and neurofilament light. These news items provide insight into how the company interprets clinical and biomarker outcomes in its target population, particularly patients with a low likelihood of Alzheimer’s disease co-pathology.
CervoMed’s news flow also includes regulatory milestones, such as written feedback from the U.S. Food and Drug Administration aligning on key aspects of the planned Phase 3 trial design in DLB. Articles may describe planned trial parameters, enrichment strategies using plasma ptau181, and the role of CDR-SB as the primary endpoint. Additional coverage highlights participation in scientific conferences, presentations at dementia and neurology meetings, and dissemination of new analyses of trial data.
Beyond clinical and regulatory updates, CRVO news features quarterly financial results, grant funding details, and changes to the company’s leadership and board composition. Announcements of executive appointments, board expansions, and investor conference participation help contextualize CervoMed’s preparation for late-stage development and potential commercialization of neflamapimod. This news page aggregates these items so readers can track how scientific results, regulatory feedback, and corporate actions evolve over time.
CervoMed (NASDAQ: CRVO) reported late-breaking Phase 2b RewinD-LB results showing neflamapimod significantly slowed clinical progression in dementia with Lewy bodies (DLB) and reduced the biomarker plasma GFAP. In an extension phase using a new capsule batch (DP Batch B), CDR-SB worsening was 52% lower versus DP Batch A at week 16 (and 82% lower in patients with ptau181 <21 pg/mL). Effects were durable to 32 weeks and correlated with GFAP reductions (median -16.0; p<0.0001). Initial randomized phase did not meet the primary endpoint due to lower-than-expected bioavailability with DP Batch A. CervoMed plans a Phase 3 registrational trial in H2 2026.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB biomarker data on December 1, 2025 at CTAD showing neflamapimod reduced plasma GFAP, increased the Aβ42/40 ratio, and trended to lower NfL in dementia with Lewy bodies (DLB).
Key controlled comparison used participants who received a higher-bioavailability capsule batch (DP Batch B) during a 32-week open-label extension versus their prior placebo period; GFAP change correlated with clinical CDR-SB change (r=0.35, p=0.036).
CervoMed (NASDAQ: CRVO) announced that neflamapimod will be featured in two presentations at the 18th CTAD conference, Dec 1–4, 2025 in San Diego.
A late-breaking oral presentation on Dec 4, 2:10 p.m. PT will present full results from the Phase 2b RewinD-LB trial at 32 weeks, delivered by Prof. John-Paul Taylor. A poster (Poster 071) on Dec 1–2 reports that neflamapimod significantly lowers plasma GFAP and examines effects on NfL and Aβ42/40. Plasma assays were run at the Neurochemistry Laboratory, Amsterdam UMC under Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) reported Q3 2025 results and clinical progress on neflamapimod for dementia with Lewy bodies (DLB). The company said it aligned with the FDA on Phase 3 trial design and plans to meet other global regulators before initiating a global pivotal trial in H2 2026. Phase 2b RewinD-LB 32-week data showed a 64% risk reduction in clinically significant worsening (CDR-SB ≥1.5) in patients with low AD co-pathology (p<0.001) and correlated reductions in plasma GFAP biomarker. Cash on hand was $27.3M (Sept 30, 2025), with funding expected into the third quarter of 2026. Q3 net loss was $7.7M.
CervoMed (NASDAQ: CRVO) announced written FDA feedback aligning on key elements of its planned global Phase 3 trial of neflamapimod for dementia with Lewy bodies (DLB).
The company plans a single, randomized, double-blind, placebo-controlled Phase 3 in ~300 DLB patients, starting in the second half of 2026, with 32-week randomized treatment and a 48-week open-label extension. The primary endpoint is change in CDR-SB; participants with Alzheimer’s co-pathology will be excluded by imaging/CSF and a plasma ptau181 cutoff (≥21.0 pg/mL).
CervoMed (NASDAQ: CRVO) appointed David Quigley to its Board of Directors effective Oct 28, 2025. Mr. Quigley is a former Senior Partner at McKinsey & Company who led Life Sciences and Private Capital practices (Senior Partner 2010–2025) and brings strategy, commercial, transaction, and M&A experience.
The appointment aligns with CervoMed’s near‑term corporate priorities: planned Phase 3 in dementia with Lewy bodies (DLB) and anticipated FDA feedback on Phase 3 design in Q4 2025. Management says Quigley’s network and commercial expertise will support Phase 3 planning, partnering, and potential commercialization of neflamapimod following Phase 2b results.
CervoMed (NASDAQ: CRVO) announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present a corporate presentation at the Emerging Growth Conference on Wednesday, October 22, 2025. The virtual presentation is scheduled for 11:25–11:55 AM ET. A live webcast and replay will be available via the provided webcast link and in the Investor section of the CervoMed website.
CervoMed (NASDAQ: CRVO) reported Phase 2b RewinD-LB results on Oct 8, 2025 showing neflamapimod activity in dementia with Lewy bodies (DLB).
In participants with plasma ptau181 <21 pg/mL (low likelihood of Alzheimer’s co-pathology), NFMD/B produced significant within-subject improvement on CDR-SB versus placebo (difference = −1.12, p=0.005) and improved clinical scales during the first 16 weeks of the Extension Phase. NFMD/B reduced risk of clinically meaningful progression by 67% versus NFMD/A over 32 weeks and 75% versus placebo over 16 weeks (both p<0.001).
Plasma GFAP fell with NFMD/B (median −16.7 pg/mL vs +5.8 pg/mL on placebo; median difference −23.1 pg/mL, p=0.016), and GFAP change correlated with CDR-SB change (p=0.036). The company expects FDA feedback on Phase 3 design in Q4 2025.
CervoMed (NASDAQ: CRVO) appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer on Oct 7, 2025 to strengthen commercialization and corporate growth as the company advances into late‑stage Phase 3 development for neflamapimod in dementia with Lewy bodies (DLB). Dr. Winton brings nearly two decades of CNS commercial experience, including leadership roles at Biogen and Inozyme and involvement in a recent acquisition. CervoMed granted an inducement option for 75,000 shares at an exercise price of $8.62 on Oct 6, 2025 that vests monthly over three years commencing Oct 31, 2025.
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.
Company management will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" on Thursday, October 9, 2025, at 8:00 AM ET. The company will also be available for one-on-one meetings with institutional investors during the conference.
FAQ
What is the current stock price of CervoMed (CRVO)?
What is the market cap of CervoMed (CRVO)?
